Rate and Proportion of Malignant Skin Biopsies for Basal Cell and Squamous Cell Carcinoma on the Face and Ears After a Single Course of Topical 5-Fluorouracil: The Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial

Topical application of gemcitabine generates microvesicle particles in human and murine skin

“…[26][27][28] Of significance, multiple studies have reported the abilities of PAFR antagonists to control the growth of cancer cells or augment the responses of therapeutic agents. 26,29,30 Given that gemcitabine chemotherapy used against multiple human malignancies either alone or in combination with other agents, exhibits adverse effects, including skin rash/necrosis, [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21] our current studies sought to determine the potential role of MVP release in the pathologic effects of topical gemcitabine application. To that end, pharmacologic approaches using human skin explants and genetic approaches using murine skin were used as relevant models.…”

“…Given that gemcitabine chemotherapy used against multiple human malignancies either alone or in combination with other agents, exhibits adverse effects, including skin rash/necrosis, 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 our current studies sought to determine the potential role of MVP release in the pathologic effects of topical gemcitabine application. To that end, pharmacologic approaches using human skin explants and genetic approaches using murine skin were used as relevant models.…”

“…In particular, topical use of chemotherapy has also been employed in the treatment of skin conditions such as non‐melanoma skin cancer, actinic keratoses, and skin aging 4,5 . However, often these drugs are associated with adverse side effects, including localized skin eruptions and necrosis as well as systemic pathologies, including ototoxicity and neutropenia 6–11 . Gemcitabine is one of the commonly used chemotherapy drugs, which has been used either alone, or in combination with other antineoplastic agents for the treatment of malignancies, including pancreatic cancer, non‐small cell lung cancer, intrahepatic cholangiocarcinoma, colorectal cancer, ovarian cancer, breast cancer, and melanoma 12–18 .…”

“… 4 , 5 However, often these drugs are associated with adverse side effects, including localized skin eruptions and necrosis as well as systemic pathologies, including ototoxicity and neutropenia. 6 , 7 , 8 , 9 , 10 , 11 Gemcitabine is one of the commonly used chemotherapy drugs, which has been used either alone, or in combination with other antineoplastic agents for the treatment of malignancies, including pancreatic cancer, non‐small cell lung cancer, intrahepatic cholangiocarcinoma, colorectal cancer, ovarian cancer, breast cancer, and melanoma. 12 , 13 , 14 , 15 , 16 , 17 , 18 Nevertheless, the development of tumor resistance mechanisms to gemcitabine therapy remained one of the ongoing challenges in its limited therapeutic efficacy.…”

Giant cutaneous squamous cell carcinoma of the popliteal fossa skin: A case report

“…Cutaneous squamous cell carcinoma (cSCC) is a non-melanoma skin and keratinocyte cancer, accounting for 20% of all skin cancers, and it is the second most common cancer worldwide[ 1 ]. Unfortunately, cSCC is not included in the national cancer registry in the United States, which makes it difficult for us to know the exact morbidity and mortality in China.…”